411 related articles for article (PubMed ID: 28011911)
1. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
[TBL] [Abstract][Full Text] [Related]
2. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
4. Impact of HPV vaccination with Gardasil® in Switzerland.
Jacot-Guillarmod M; Pasquier J; Greub G; Bongiovanni M; Achtari C; Sahli R
BMC Infect Dis; 2017 Dec; 17(1):790. PubMed ID: 29273004
[TBL] [Abstract][Full Text] [Related]
5. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
6. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013.
Dunne EF; Naleway A; Smith N; Crane B; Weinmann S; Braxton J; Steinau M; Unger ER; Markowitz LE
J Infect Dis; 2015 Dec; 212(12):1970-5. PubMed ID: 26123561
[TBL] [Abstract][Full Text] [Related]
9. Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women.
Whittemore D; Ding L; Widdice LE; Brown DA; Bernstein DI; Franco EL; Kahn JA
J Womens Health (Larchmt); 2016 Nov; 25(11):1153-1158. PubMed ID: 27754751
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer risk perceptions, sexual risk behaviors and sexually transmitted infections among Bivalent Human Papillomavirus vaccinated and non-vaccinated young women in Uganda - 5 year follow up study.
Kumakech E; Andersson S; Wabinga H; Musubika C; Kirimunda S; Berggren V
BMC Womens Health; 2017 Jun; 17(1):40. PubMed ID: 28576143
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
12. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
13. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine.
Bretagne CH; Jooste V; Guenat D; Riethmuller D; Bouvier AM; Bedgedjian I; Prétet JL; Valmary-Degano S; Mougin C
J Gynecol Obstet Hum Reprod; 2018 Dec; 47(10):525-531. PubMed ID: 29807205
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
Guo F; Hirth JM; Berenson AB
Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
[TBL] [Abstract][Full Text] [Related]
16. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.
Mesher D; Panwar K; Thomas SL; Beddows S; Soldan K
BMJ Open; 2016 Feb; 6(2):e009915. PubMed ID: 26868944
[TBL] [Abstract][Full Text] [Related]
17. Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005.
Dunne EF; Flagg EW; Unger ER; Hsu K; Ghanen K; Kerndt P; Shlay JC; Koutsky LA; Datta DS; Panicker G; Zaidi A; Weinstock H; Markowitz LE
Sex Transm Dis; 2014 Jan; 41(1):46-9. PubMed ID: 24326582
[TBL] [Abstract][Full Text] [Related]
18. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination.
Markowitz LE; Naleway AL; Lewis RM; Crane B; Querec TD; Weinmann S; Steinau M; Unger ER
Vaccine; 2019 Jun; 37(29):3918-3924. PubMed ID: 31160099
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
20. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
